Combangio

Combangio, Inc. is a clinical-stage company developing regenerative biologics for severe ocular diseases. The company’s CMB-012 (now referred to as KPI-012) is a novel investigational secretome therapy. KPI-012 is designed to treat Persistent Corneal Epithelial Defect (PCED), a condition characterized by corneal defects that fail to heal or are resistant to conventional treatments, as well as other similar ocular conditions.